new
formul
nf
subcutan
sc
interferon
ifn
develop
attempt
improv
inject
toler
immunogen
compar
antivir
gene
isg
activ
sc
nf
sc
origin
formul
sc
equival
unit
amount
compar
formul
demonstr
similar
antivir
activ
induc
similar
level
isg
mrna
howev
weight
basi
ngml
significantli
sc
need
equal
antivir
activ
either
sc
formul
sc
formul
induc
significantli
higher
level
isg
mrna
sc
interferon
beta
antivir
immunomodulatori
agent
demonstr
efficaci
safeti
treatment
relaps
multipl
sclerosi
ms
random
doubleblind
placebocontrol
clinic
trial
therapi
shown
reduc
relaps
rate
brain
lesion
develop
patient
relaps
form
ms
inde
subcutan
sc
formul
rebif
merck
serono
sa
geneva
switzerland
administ
three
time
weekli
tiw
intramuscular
im
formul
avonex
biogen
idecelan
cambridg
usa
administ
weekli
also
shown
delay
progress
physic
disabl
patient
relaps
form
ms
three
formul
current
approv
usa
treatment
patient
relaps
form
ms
sc
tiw
rebif
origin
formul
refer
articl
sc
administ
im
weekli
avonex
sc
administ
everi
day
betaseron
betaferon
bayer
healthcar
pharmaceut
wayn
nj
usa
extavia
novarti
pharmaceut
corpor
east
hanov
nj
usa
respons
therapi
vari
type
prepar
may
impact
drug
formul
dose
regimen
rout
administr
exampl
headtohead
comparison
differ
formul
demonstr
higher
frequent
dose
greater
efficaci
compar
lower
less
frequent
dose
regimen
differ
formul
treatment
relaps
ms
treatment
patient
relaps
ms
associ
develop
neutral
antibodi
nab
although
full
clinic
impact
antiifn
antibodi
complet
known
presenc
high
titer
nab
reduc
therapeut
effect
treatment
new
sc
formul
rebif
new
formul
nf
merck
bari
itali
produc
without
fetal
bovin
serum
without
human
serum
albumin
excipi
goal
improv
inject
toler
reduc
immunogen
develop
vivo
administr
sc
nf
mous
model
suggest
slower
weaker
develop
nab
compar
sc
biolog
activ
assess
vitro
assay
supplement
vivo
data
therebi
help
fulli
character
particular
therapeut
agent
evid
previou
studi
indic
antivir
biolog
activ
may
vari
among
differ
formul
specif
measur
biolog
activ
includ
inhibit
viral
replic
enhanc
express
mrna
induc
object
current
vitro
studi
compar
antivir
gene
isg
express
activ
sc
nf
origin
sc
formul
sc
use
addit
compar
antivir
activ
induct
isg
express
evalu
three
formul
sc
rebif
origin
formul
lot
number
industria
farmaceutica
serono
rome
itali
sc
nf
rebif
serumfre
formul
lot
number
c
scagnolari
et
al
industria
farmaceutica
serono
sc
betaferon
lot
number
bayer
schere
berlin
germani
antivir
activ
assess
use
stomat
viru
vsv
cytopath
effect
cpe
assay
measur
cell
viabil
follow
infect
human
lung
carcinoma
cell
lytic
vsv
indiana
strain
cell
zooprophylact
institut
brescia
itali
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
fc
sial
rome
itali
mm
lglutamin
sial
gentamycin
sial
mm
hepe
buffer
solut
sial
cell
seed
cell
per
well
plate
falcon
tm
becton
dickinson
labwar
lincoln
park
nj
usa
hr
triplic
cell
cultur
incub
serial
dilut
formul
hr
test
well
fill
ml
medium
serv
viru
cell
control
cell
monolay
wash
dmem
ifntreat
control
virus
inocul
vsv
multipl
infect
tcid
tissu
cultur
infecti
dose
cell
adsorpt
c
hr
excess
viru
inoculum
remov
cell
monolay
wash
phosphatebuff
salin
well
fill
complet
medium
total
volum
mlwell
infect
vsv
allow
progress
hr
accord
time
requir
specif
cytopath
effect
becom
clearli
visibl
optic
microscopi
cultur
supernat
collect
titrat
vsv
carri
mous
fibroblast
cell
zooprophylact
institut
cell
maintain
minim
essenti
medium
fc
sial
mm
lglutamin
sial
gentamycin
sial
titrat
vsv
perform
determin
tcid
ml
accord
method
reed
muench
seri
threefold
dilut
vsv
inocula
ad
cell
monolay
incub
hr
order
detect
vsvinduc
cpe
cell
monolay
stain
crystal
violet
ethanol
dye
taken
cell
elut
acet
acid
absorb
measur
nm
enzymelink
immunosorb
assay
micropl
reader
varioskan
flash
spectral
scan
multimod
reader
thermo
fischer
pittsburgh
pa
usa
antivir
activ
calcul
doserespons
curv
viral
yield
obtain
ifntreat
cell
express
term
percentag
viral
inhibit
respect
yield
virusinfect
control
cell
result
analys
express
term
inhibitori
concentr
ic
calcul
intern
unit
iu
ml
ngml
specif
activ
differ
formul
consid
specif
activ
use
miumg
sc
miumg
sc
specif
activ
valu
provid
manufactur
obtain
compar
antivir
activ
formul
world
health
organ
refer
standard
recombin
human
furthermor
antivir
activ
formul
also
compar
measur
vsv
yield
reduct
cell
treat
time
ic
formul
obtain
perform
experi
describ
reduct
vsv
yield
cell
measur
rel
vsv
yield
control
cell
treat
induct
isg
express
assess
use
quantit
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
myxoviru
resist
protein
mxa
adenosin
deaminas
rnaspecif
mrna
cell
incub
variou
concentr
formul
hr
end
incub
total
cellular
rna
extract
cell
use
trizol
gibco
brl
new
york
ny
usa
accord
manufactur
instruct
rna
dissolv
rnasefre
water
quantit
isg
mrna
perform
real
time
exonucleas
rtpcr
taqman
assay
use
abi
sequenc
detector
appli
biosystem
foster
citi
ca
usa
gener
cdna
previous
describ
follow
primer
pair
probe
mxa
mxa
f
mxa
r
mxa
p
fam
tamra
ada
adar
f
adar
r
adar
p
famcacttcccagggagcacgg
tamra
f
r
p
fam
tamra
ad
univers
pcr
master
mix
appli
biosystem
foster
citi
ca
usa
nm
nm
respect
final
volum
coamplif
betaglucuronidas
gene
gu
assayondemand
appli
biosystem
use
normal
amount
total
rna
present
use
threshold
cycl
rel
quantif
accord
supplier
guidelin
ct
method
threshold
cycl
ct
valu
pcr
cycl
amplif
plot
cross
threshold
line
ct
valu
amplif
reaction
perform
cell
vitro
treatment
use
calcul
differ
two
aspect
biolog
activ
investig
antivir
activ
induct
isg
express
three
formul
compar
basi
unit
iuml
weight
ngml
three
replic
two
experi
run
measur
antivir
activ
term
ic
provid
six
observ
formul
unit
basi
six
observ
weight
basi
mean
standard
deviat
calcul
formul
display
bar
chart
ic
formul
measur
six
replic
formul
run
independ
observ
measur
vsv
yield
reduct
cell
treat
time
ic
formul
antivir
activ
formul
compar
use
student
ttest
analysi
perform
use
spss
version
window
spss
inc
chicago
il
usa
four
differ
concentr
formul
mxa
gene
express
activ
measur
three
replic
express
measur
six
replic
sinc
concentr
differ
factor
logarithm
scale
use
present
result
could
display
meaning
graph
student
ttest
use
compar
rel
gene
express
mxa
among
three
formul
amount
dilut
three
formul
demonstr
similar
antivir
activ
cell
infect
vsv
equival
unit
amount
formul
compar
differ
mean
ic
iuml
valu
standard
deviat
among
sc
iuml
nf
sc
iuml
sc
iuml
formul
figur
importantli
antivir
activ
similar
sc
sc
nf
formul
compar
weight
basi
ngml
substanti
sc
need
equal
antivir
activ
either
sc
sc
nf
specif
mean
ic
ngml
valu
standard
deviat
sc
ngml
nf
sc
ngml
sc
ngml
figur
signific
differ
sc
sc
nf
antivir
activ
formul
compar
weight
basi
also
measur
vsv
yield
reduct
cell
treat
time
ic
formul
time
ic
vsv
yield
reduct
significantli
differ
sc
sc
nf
tabl
vsv
yield
reduct
also
significantli
differ
sc
either
sc
formul
concentr
correspond
time
ic
formul
compar
basi
ifn
unit
amount
iuml
howev
concentr
correspond
time
ic
formul
compar
weight
basi
ngml
vsv
yield
reduct
higher
sc
sc
nf
sc
concentr
correspond
time
ic
formul
compar
weight
basi
ngml
vsv
yield
reduct
significantli
differ
sc
either
sc
formul
differ
isg
express
determin
induct
mxa
mrna
consist
observ
antivir
activ
formul
equival
unit
amount
three
formul
compar
induc
similar
transcript
level
mxa
iuml
iuml
signific
differ
mean
foldchang
isg
mrna
express
sc
sc
nf
sc
figur
isg
transcript
level
similar
origin
sc
formul
sc
nf
formul
compar
weight
ngml
ngml
sc
sc
nf
induc
higher
transcript
level
mxa
compar
sc
figur
signific
differ
isg
express
sc
sc
nf
object
current
articl
compar
biolog
activ
sc
nf
sc
sc
use
addit
compar
antivir
biolog
activ
formul
compar
measur
reduct
cpe
human
lung
carcinoma
cell
follow
infect
vsv
level
mxa
mrna
encod
antivir
protein
commonli
assay
cell
cultur
expos
type
ifn
vitro
measur
ifn
biolog
activ
equival
unit
amount
formul
compar
sc
sc
nf
sc
demonstr
similar
level
antivir
activ
term
ic
howev
formul
compar
weight
basi
ngml
significantli
sc
requir
equal
antivir
activ
either
formul
compar
weight
basi
ngml
ngml
sc
sc
nf
induc
significantli
higher
mrna
level
b
mxa
f
compar
sc
p
comparison
use
student
ttest
calcul
accord
specif
activ
sc
miumg
sc
miumg
adenosin
deaminas
rnaspecif
interferon
beta
interferon
stimul
gene
iu
intern
unit
mxa
myxoviru
resist
protein
nf
new
formul
sc
subcutan
formul
sc
term
ic
similarli
concentr
correspond
time
ic
formul
compar
weight
basi
smaller
reduct
vsv
yield
observ
sc
either
sc
formul
howev
concentr
correspond
time
ic
formul
compar
weight
basi
vsv
yield
reduct
similar
three
formul
probabl
concentr
plateau
phase
doserespons
curv
reach
differ
antivir
activ
formul
longer
observ
importantli
differ
sc
sc
formul
weight
basi
demonstr
measur
express
wellestablish
isg
particular
sc
sc
nf
induc
similar
level
isg
express
induc
significantli
higher
mrna
level
isg
compar
sc
find
suggest
weight
basi
biolog
activ
equival
formul
sc
greater
sc
thu
greater
weight
sc
may
need
achiev
biolog
respons
sc
despit
fact
sc
molecular
weight
approxim
dalton
approxim
sc
approxim
dalton
antonetti
colleagu
examin
antivir
activ
sc
use
sc
use
use
cpe
assay
system
show
antivir
activ
approxim
time
greater
ngml
versu
ngml
respect
similar
differ
biolog
activ
formul
report
previous
find
pilot
studi
emphas
potenti
import
determin
rel
biolog
activ
differ
formul
suggest
amount
protein
requir
achiev
biolog
respons
might
higher
formul
notabl
limit
studi
im
avonex
includ
comparison
avail
formul
date
publish
studi
compar
within
assay
system
biolog
activ
three
formul
current
approv
treatment
relaps
ms
second
potenti
limit
present
studi
singl
viru
cell
model
system
use
studi
biolog
activ
formul
therefor
addit
studi
requir
compar
biolog
activ
approv
formul
studi
employ
model
system
also
assay
system
differ
ifnsensit
virus
well
type
ifnsensit
cell
conclus
biolog
activ
found
vari
among
differ
formul
result
articl
indic
respect
specif
assay
use
sc
sc
nf
exhibit
equival
biolog
activ
furthermor
weight
basi
biolog
activ
sc
formul
greater
sc
measur
method
suggest
greater
amount
sc
may
need
achiev
vitro
respons
sc
relev
vitro
find
clinic
effect
formul
relaps
ms
unknown
howev
examin
vitro
biolog
respons
demonstr
distinct
properti
compound
relev
need
investig
